乌帕替尼维持治疗克罗恩病:随机3期U-ENDURE研究的最终结果
U-ENDURE研究纳入673例对乌帕替尼45 mg每日一次诱导治疗12周有临床应答的克罗恩病患者,按1:1:1随机接受乌帕替尼15 mg(n=221)、30 mg(n=229)或安慰剂(n=223)维持治疗52周。第52周,乌帕替尼15 mg和30 mg组CDAI临床缓解率分别为36.2%和51.5%,高于安慰剂的15.2%;内镜应答率分别为27.3%和40.7%,高于安慰剂的7.2%。安全性方面未发现新的安全信号。
要点
- 第52周CDAI临床缓解率:乌帕替尼15 mg组36.2%、30 mg组51.5%,均高于安慰剂组15.2%。
- 第52周内镜应答率:乌帕替尼15 mg组27.3%、30 mg组40.7%,均高于安慰剂组7.2%。
- 除COVID-19和导致提前停药的AE外,乌帕替尼组治疗中出现的不良事件暴露调整发生率数值上低于安慰剂组。
核心结论
- 与主要分析一致,乌帕替尼在克罗恩病患者中实现临床和内镜终点方面比安慰剂更有效,安全性特征保持一致,无新安全信号。
研究设计与样本
- 3期随机、双盲、安慰剂对照维持试验U-ENDURE(NCT03345823),总人群N=673。
- 对乌帕替尼45 mg每日一次诱导治疗12周有临床应答者按1:1:1随机接受乌帕替尼15 mg每日一次(n=221)、乌帕替尼30 mg每日一次(n=229)或安慰剂(n=223)维持治疗52周。
- 共同主要终点为第52周克罗恩病活动指数(CDAI)临床缓解和内镜应答,安全性评估至第52周。
主要发现
- 第52周CDAI临床缓解率:乌帕替尼15 mg组36.2%、乌帕替尼30 mg组51.5%,安慰剂组15.2%。
- 第52周内镜应答率:乌帕替尼15 mg组27.3%、乌帕替尼30 mg组40.7%,安慰剂组7.2%。
- 治疗中出现的不良事件暴露调整发生率:乌帕替尼15 mg组351.3/100患者年、30 mg组324.5/100患者年,安慰剂组462.8/100患者年,乌帕替尼组数值上低于安慰剂组,但COVID-19和导致提前停用研究治疗的不良事件除外。
- 任何治疗组均未报告死亡、活动性结核、淋巴瘤、非黑色素瘤皮肤癌、经裁定的主要心血管不良事件或静脉血栓栓塞事件。
- 带状疱疹感染在乌帕替尼组比安慰剂组更常见,所有均为非严重性,多数累及单一皮节。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Upadacitinib, an oral, reversible Janus kinase inhibitor, demonstrated efficacy and safety in patients with Crohn's disease in 2 phase III induction trials (U-EXCEL and U-EXCEED) and in a primary analysis of the first 502 patients entering the subsequent maintenance trial (U-ENDURE). Here, we present the overall results of the entire population of U-ENDURE (N = 673). METHODS: Clinical responders to 12 weeks of upadacitinib 45 mg once daily (QD) induction were randomized (1:1:1) to receive upadacitinib 15 mg QD (n = 221), upadacitinib 30 mg QD (n = 229), or placebo (n = 223) as maintenance therapy for 52 weeks. Coprimary endpoints were Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 52. Safety was assessed through week 52. RESULTS: At week 52, more upadacitinib-treated vs placebo patients achieved CDAI clinical remission (upadacitinib 15 mg, 36.2% and upadacitinib 30 mg, 51.5% vs placebo, 15.2%). The rates of endoscopic response were 27.3% for upadacitinib 15 mg and 40.7% for upadacitinib 30 mg vs 7.2% for placebo. Exposure-adjusted event rates for treatment-emergent adverse events were numerically lower with upadacitinib 15 mg and 30 mg vs placebo (351.3 and 324.5 per 100 patient-years, respectively, vs 462.8 per 100 patient-years) except for COVID-19 and adverse events leading to early discontinuation of study treatment. No deaths, active tuberculosis, lymphoma, nonmelanoma skin cancer, adjudicated major cardiovascular adverse events, or venous thromboembolic events were reported from any treatment group. Herpes zoster infections occurred more frequently in the upadacitinib groups compared with placebo; all were nonserious, and most involved a single dermatome. CONCLUSIONS: Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in patients with Crohn's disease. The safety profile remained consistent with no new safety signals. CLINICALTRIALS: gov Number: NCT03345823.
引用
- Panaccione R, Regueiro M, Lee SD, et al. Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. Clin Gastroenterol Hepatol. 2025. PMID: 40738276. doi:10.1016/j.cgh.2025.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。